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Background. Niemann-Pick Type C (NPC) disease is a neurodegenerative disease that is characterized by the accumulation of
cholesterol and glycosphingolipids in the late endocytic pathway. The majority of NPC cases are due to mutations in the NPC1
gene. The precise function of this gene is not yet known. Methodology/Principal Findings. Using cDNA microarrays, we
analyzed the genome-wide expression patterns of human fibroblasts homozygous for the I1061T NPC1 mutation that is
characterized by a severe defect in the intracellular processing of low density lipoprotein-derived cholesterol. A distinct gene
expression profile was identified in NPC fibroblasts from different individuals when compared with fibroblasts isolated from
normal subjects. As expected, NPC1 mutant cells displayed an inappropriate homeostatic response to accumulated
intracellular cholesterol. In addition, a number of striking parallels were observed between NPC disease and Alzheimer’s
disease. Conclusions/Significance. Many genes involved in the trafficking and processing of amyloid precursor protein and
the microtubule binding protein, tau, were more highly expressed. Numerous genes important for membrane traffic and the
cellular regulation of calcium, metals and other ions were upregulated. Finally, NPC fibroblasts exhibited a gene expression
profile indicative of oxidative stress. These changes are likely contributors to the pathophysiology of Niemann-Pick Type C
disease.
Citation: Reddy JV, Ganley IG, Pfeffer SR (2006) Clues to Neuro-Degeneration in Niemann-Pick Type C Disease from Global Gene Expression
Profiling. PLoS ONE 1(1): e19. doi:10.1371/journal.pone.0000019
INTRODUCTION
Niemann Pick Type C disease (NPC) is a fatal, autosomal recessive
neurodegenerative disease due to mutations in the NPC1 or NPC2
genes [1,2]. NPC is associated with an inability to process cellular
cholesterol, which accumulates together with glycosphingolipids
within lysosomes of affected individuals. The disease is often
diagnosed in early childhood, with patients typically displaying
cerebellar ataxia, difficulty speaking and swallowing, and pro-
gressive dementia. Mutations in the NPC1 gene account for
approximately 95% of NPC cases.
NPC1 is a 1278 amino acid protein with 13 transmembrane
domains that is important for normal cholesterol homeostasis [3].
NPC1 transmembrane domains 3–7 comprise a so-called sterol
sensing domain that is related to hydroxymethlyglutaryl CoA
reductase [4], sterol regulatory element-binding protein cleavage
activating protein (SCAP; [5], PATCHED [6,7]) and NPC1-like
protein, NPC1L1 [8]. The NPC1 protein was recently shown to
bind cholesterol [9]. Mutations in the NPC1 sterol sensing domain
can cause disease, as can mutations throughout the protein, the
bulk of which resides within the membrane bilayer or within the
lumen of late endosomes [1].
To begin to understand how loss of NPC1 function leads to
neurodegeneration, we have examined the global pattern of gene
expression in primary fibroblast cells from NPC patients. To avoid
possible phenotypic variation between different mutant alleles, we
designed our analysis using cells from different individuals who
each carried the identical, homozygous mutations within their
NPC1 loci. The most common NPC-1 mutation described is
I1061T, which accounts for 20% of the alleles in the United
Kingdom and France and about 15% in the United States [10,11]
and leads to a severe disruption of cholesterol processing.
Homozygous carriers of the I1061T mutation present with
a relatively mild neurological form of the disease with onset in
juvenile years; importantly, their clinical presentation is homoge-
neous. In our experimental design, we hoped that gene expression
differences between any two individuals would be averaged out,
highlighting changes due to this specific mutation at both NPC1
alleles. As shown here, NPC1 fibroblasts showed highly significant
differences when compared with normal fibroblast controls. The
specific gene expression changes observed provide important clues
to the pathophysiology of NPC disease.
RESULTS AND DISCUSSION
Primary skin fibroblasts isolated from four patients homozygous
for the I1061T mutation and four control individuals were
cultured under identical conditions. RNA was isolated from all
samples and hybridized to cDNA microarrays consisting of
approximately 43,000 elements representing approximately
36,000 genes. Analysis of the data using a supervised hierarchical
clustering method identified a gene expression pattern that was
unique and consistent among NPC fibroblasts (Figure 1A). To
identify statistically significant gene expression profile changes that
are likely to result from the I1061T mutation in the NPC1 gene we
used SAM (Significance Analysis of Microarrays; [12]).
SAM identifies genes with statistically significant changes in
expression by assimilating a set of gene-specific t tests. Each gene is
assigned a score on the basis of its change in gene expression
relative to the standard deviation of repeated measurements for
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potentially significant. The percentage of such genes identified by
chance is defined as the false discovery rate. Figure 1B shows the
distribution of the ,43,000 elements analyzed in this study. Many
more genes were found to be significantly up-regulated (3578, red
points) than down-regulated (699, green points) when comparing
normal and NPC1 cells (Fig. 1B). SAM identified approximately
3600 significant genes in our data set with an estimated false
discovery rate of 5%; ,1300 genes showed $1.5 fold up-
regulation compared with normal cells. The large number of
upregulated genes suggests that NPC cells are compensating to
survive under challenging circumstances. An Excel list of all
significant genes showing a ,2% false discovery rate is included
for the reader as a supplemental file (Dataset S1).
It is important to note that the absolute fold change in the level
of a specific transcript need not be high to be highly significant,
and to have significant consequences for cell physiology [12]. For
many of the genes shown, the potential false discovery rate was less
than 1%, and as described below, several of the changes have been
verified at the protein level.
Initial analysis of the upregulated genes confirmed the validity
of our experimental protocol, as genes expected to be upregulated
in cells lacking NPC1 function were upregulated: for example, the
gene encoding NPC2 protein was upregulated 1.7 fold and the
gene encoding NPC1-like protein, NPC1L1 was upregulated 1.3
fold (Table 1). This confirms previous work demonstrating the
upregulation of NPC2 at the protein level in NPC1 fibroblasts
[13,14].
Cholesterol Homeostasis
In normal cells, cholesterol levels are tightly regulated by a number
of mechanisms that include cholesterol uptake, storage and efflux
[15]. At the transcriptional level, sterol regulatory element-binding
proteins regulate the expression of a large number of genes
involved in the synthesis and uptake of cholesterol, fatty acids,
triglycerides and phospholipids, as well as NADPH that is needed
for lipid and cholesterol synthesis [16]. In the presence of adequate
cholesterol in the endoplasmic reticulum (ER), these transcription
factors fail to translocate to the nucleus, and genes involved in
cholesterol synthesis and uptake are no longer activated.
NPC cells are well documented in terms of their inability to
respond to the accumulation of unesterified cholesterol within late
endocytic compartments. In these cells, LDL receptor expression is
not down-regulated and consequently, LDL uptake continues to
occur despite the increased cellular content of free cholesterol [17].
Microarray analysis confirmed this dysregulation: elevated expres-
sion (1.5 fold) of the LDL receptor gene was readily detected in
NPC fibroblasts homozygous for the I1061T mutation when
compared with normal fibroblasts (Table 1).
Cellular cholesterol is also regulated by Liver X Receptors
(LXRs), which are activated by cholesterol-derived oxysterols.
LXRs activate target genes that participate in the efflux of cellular
cholesterol, including the transporters, ABCA1 and ABCG5/
ABCG8. NPC cells are defective in oxysterol generation and
subsequent LXR activation [18]. Previous, direct measurements of
ABCA1 mRNA indicated significantly less upregulation of ABCA1
gene expression in NPC1
2/2 cells upon cholesterol addition than
observed in wild type cells [19]. ABCA1 and ABCG5 expression
levels were altered in NPC cells in accordance with earlier reports
(Table 1). In addition, we observed increased expression of
ABCA7, a non-LXR regulated transporter that has the ability to
support apolipoprotein-mediated release of cellular cholesterol and
phospholipid (Table 1, ref. [20]).
Increased expression of several proteins from the oxysterol
binding protein family (OSBPL3, OSBPL6 and OSBPL8) was also
detected (Table 1). One function ascribed to this protein family is
non-vesicular cholesterol transfer between the ER and the plasma
membrane [21]. Both OSBPL3 and OSBPL6 contain targeting
sequences for the ER and plasma membrane. Interestingly,
overexpression of the related OSBP2 protein leads to the
activation of cholesterol synthesis and LDL receptor upregulation,
perhaps by enhancing ER cholesterol efflux [21].
Links to Neurodegenerative Disease
As in Alzheimer’s disease, defects in the processing of the amyloid
precursor protein (APP) are well documented for NPC cells [22–
25]. APP can be processed via two different pathways. In the non-
amyloidogenic pathway, APP is cleaved by alpha-secretase to
generate a C-terminal fragment (CTF) followed by cleavage with
the gamma-secretase complex, resulting in the generation of two
non-amyloidogenic peptides. In the amyloidogenic pathway, APP
is cleaved by beta-secretase prior to cleavage with gamma-
secretase, generating the Abeta fragments that are associated with
amyloid plaque formation. Burns et al. [23] have shown that
mouse NPC cells show enhanced gamma secretase activity,
leading to increased Abeta, Abeta42 and beta-CTF production.
Figure 1. Gene expression is significantly altered in NPC1 fibroblasts. (A)
Supervised hierarchical clustering of the top 200 genes after SAM
analysis. The dendrogram at the top shows clustering of NPC and
control fibroblasts into distinct groups. Genes with higher expression
are shown in red; genes with lower expression are shown in green. Gray
bars indicate missing data. Cell lines clustered in the following order
(left to right): control lines AG10803, GM05659, GM09503, GM03726;
NPC-1 lines GM017909, 59413, 83.16, and GM18453. (B) Significance
Analysis of Microarrays [12] was used to identify genes that varied in
expression between NPC fibroblasts and control fibroblasts from
healthy patients. The plot of the data from 43,000 elements reveals
approximately 3600 significant genes that have increased expression in
NPC fibroblasts (shown in red).
doi:10.1371/journal.pone.0000019.g001
Global Gene Expression in NPC
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e19They also noted an alteration in the localization of presenilin 1 to
some Rab5-positive, putative early endosomes in NPC cells [23].
Increased levels of Abeta, Abeta 42 and beta-CTF were also
reported by others [22,24,25].
Consistent with previous analyses of mouse NPC cells [23], we
found little difference in the mRNA and protein levels of full
length amyloid precursor protein, beta secretases (BACE), or the
level of the gamma secretase component, presenilin, in human
NPC1 cells compared with normal fibroblasts (Figure 2). At the
protein level, Nicastrin polypeptide was increased, which could
contribute to increased gamma secretase activity. Importantly, we
confirmed a significant increase in the generation of amyloid C-
terminal fragments at the protein level, in human NPC-1
fibroblasts (Figure 2).
Additionally, expression of the amyloid beta precursor binding
protein 2 (APBB2 or Fe65-like), was upregulated 2.6 fold with high
significance (0.1% false discovery rate), and was among the highest
upregulated genes in our entire data set (Table 2). This protein is
thought to regulate the intracellular transport of the amyloid
precursor protein. As shown in Figure 2, both the mRNA and
APBB2 protein were upregulated ,2.5 fold in NPC1 cells as
determined by immunoblotting of cell extracts. APBB2 interacts
with the cytoplasmic domain of APP [26,27]. The association of
APBB2 with APP is required for subsequent processing of APP
CTF’s by gamma secretases, and overexpression of APBB2 leads
to the increased generation of the amyloidogenic Abeta42
fragment [27]. Upregulation of APBB2 in NPC fibroblasts may
contribute to the increased generation of Abeta42 in NPC cells.
Recent work has indicated that Abeta42 may directly activate
neutral sphingomyelinases [28]. This activation would potentially
increase ceramide generation in NPC1 cells and may be linked to
oxidative stress. A neutral sphingomyelinase activating protein
mRNA (NSMAF) was upregulated in our dataset (Table 2).
Genes encoding LDL receptor-related proteins (LRP1, LRP2
and LRP6) were upregulated 1.8, 2.2 and 2.7 fold, respectively, in
NPC fibroblasts (Table 2 and Supp. Table 3). LRP1 interacts with
APP and may enhance its internalization, thereby favoring initial
intracellular APP cleavage by beta-secretase [29]. APP undergoes
axonal transport to nerve terminals in a complex with the signaling
protein, MAPK8IP1 in a kinesin-1 dependent manner [30,31]. A
Kinesin-1 component (KLC2) and MAPK8IP1 were all upregu-
lated in NPC cells, and could contribute to the transport of APP in
NPC neurons (Table 2). In summary, genes encoding multiple
factors that contribute to the generation of amyloid are expressed
at higher levels in NPC1 cells.
Table 1. Genes involved in Cholesterol Homeostasis are upregulated in NPC cells.
..................................................................................................................................................
Accession number Symbol Name Fold Change False Discovery Rate
AI206275 ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 1.4 0.5
AI668630 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1.4 0.9
T97780 ABCG5 ATP-binding cassette, sub-family G (WHITE), member 5 (sterolin 1) 1.4 2.8
AA255954 ACBD3 Acyl-Coenzyme A binding domain containing 3 1.4 1.9
AA702706 CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 43 1.4 1.2
AA992540 CYP7B1 Cytochrome P450, family 7, subfamily B, polypeptide 1 1.7 0.1
AA928708 CYP8B1 Cytochrome P450, family 8, subfamily B, polypeptide 1 1.8 0
AA669312 LDLR Low density lipoprotein receptor 1.4 1.9
AA976046 LPL Lipoprotein lipase 1.8 0.1
AA676945 NPC1L1 NPC1 (Niemann-Pick disease, type C1, gene)-like 1 1.3 3.6
AA630449 NPC2 Niemann-Pick disease, type C2 1.7 0.4
AI342012 MSR1 Macrophage scavenger receptor 1 1.6 0.2
H10059 OSBPL3 Oxysterol binding protein-like 3 1.4 1.2
AI094626 OSBPL6 Oxysterol binding protein-like 6 1.5 1.2
AA126551 OSBPL8 Oxysterol binding protein-like 8 1.5 0.4
DOI: 10.1371/journal.pone.0000019.t001
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Figure 2. Links to Alzheimer’s disease at the mRNA and protein levels in
NPC Cells. Protein levels in control and NPC-1 fibroblasts, determined by
immunoblot (panel A), are quantified in B (dark shaded bars); mRNA
levels from microarray data are shown in light shaded bars for
comparison.
doi:10.1371/journal.pone.0000019.g002
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The expression of a number of calcium-regulated and regulating
proteins was increased in NPC fibroblasts (Table 3). These include
voltage gated calcium channels such as CACNA1C, calcium
dependent protein kinases (CAMK1 and CAMK4), phospholipase
C, ryanodine receptor and also calpains (CAPN5). The upregula-
tion of these proteins is consistent with altered cytosolic calcium
levels in NPC1 mutant cells. Defects in calcium regulation have
been reported for a number of neurodegenerative diseases (see
[32,33] for review). Moreover, Abeta42 has been shown to disrupt
intracellular calcium regulation which may play a role in
Alzheimer’s disease [34]. Abeta increases the activation of L type
voltage gated calcium channels [35,36] and has even been
proposed to itself form a cation channel [37].
Tau protein One of the major features of both Alzheimer’s
and NPC diseases is the accumulation of neurofibrillary tangles in
the brain. A major component of such tangles is an abnormally
phosphorylated form of the microtubule binding protein, tau [38].
Although the mechanism of tangle formation is unknown,
phosphorylation of the tau protein C-terminus is thought to
disrupt microtubule binding and trigger subsequent aggregation.
NPC fibroblasts displayed enhanced expression of a number of
kinases that may participate in tau phosphorylation (TTBK1,
MAPK8, PRKCG) (Table 2, III; [39–41]). Divalent cations such
as calcium have also been implicated in the formation of
phosphorylated tau aggregates [42]. As discussed earlier, many
alterations in gene expression suggest an alteration in calcium
homeostasis in NPC cells (Table 3).
Table 2. Genes associated with Alzheimer’s disease are upregulated in NPC cells.
..................................................................................................................................................
Accession
number Symbol Name Fold Change False Discovery Rate
AA553762 APBB2 Amyloid beta (A4) precursor protein-binding, family B, member 2 (Fe65-like) 2.6 0
AA234298 BDNF Brain-derived neurotrophic factor 1.7 0.2
W47179 CTSB Cathepsin B 1.5 1.3
AA121031 ERBB4 V-erb-a erythroblastic leukemia viral oncogene homolog 4 1.9 0
AA626316 KLC2 Likely ortholog of kinesin light chain 2 1.6 0
AA464566 LRP1 Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 1.8 0.1
AI821048 LRP2 Low density lipoprotein-related protein 2 2.2 0.1
W47666 MAPK8 Mitogen-activated protein kinase 8 1.4 1.6
AI206407 MAPK8IP1 Mitogen-activated protein kinase 8 interacting protein 1 1.5 0.4
AA046107 NSMAF Neutral sphingomyelinase (N-SMase) activation associated factor 1.5 0.2
N63949 NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 1.4 1.7
AI360356 SYP Synaptophysin 1.5 0.2
AA564047 TGM4 Transglutaminase 4 (prostate) 2.9 0
N80413 TTBK1 Tau tubulin kinase 1 1.4 0.9
DOI: 10.1371/journal.pone.0000019.t002
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Table 3. Genes associated with calcium regulation are upregulated in NPC fibroblasts.
..................................................................................................................................................
Accession number Symbol Name Fold Change False Discovery Rate
AW004620 CAMK1 Calcium/calmodulin-dependent protein kinase I 1.8 0.1
AA903749 CAMK1D Calcium/calmodulin-dependent protein kinase ID 1.6 0.1
AA455227 CAMK4 Calcium/calmodulin-dependent protein kinase IV 1.4 1.6
AA521411 CAMLG Calcium modulating ligand 1.6 1.7
AA458480 CAMTA2 Calmodulin binding transcription activator 2 1.6 0.2
AA587773 CANT1 Calcium activated nucleotidase 1 1.9 0.1
H81543 CAPN5 Calpain 5 2.2 0
AA412186 CAST Calpastatin 1.5 0.2
AA857871 NFATC3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 2 0
AI820551 P2RY1 Purinergic receptor P2Y, G-protein coupled, 1 2.5 0
R89714 PRKCG Protein kinase C, gamma 1.6 0.2
AA815407 RYR1 Ryanodine receptor 1 (skeletal) 1.5 1.1
DOI: 10.1371/journal.pone.0000019.t003
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PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e19Transglutaminase catalyzes the formation of insoluble tau
aggregates in vitro, and increased transglutaminase activity has
been observed in Alzheimer’s disease [43,44]. Transglutaminase 4
is significantly upregulated in NPC fibroblasts, and may contribute
to tau aggregation in NPC disease [Table 2).
Cellular toxicity induced in NPC disease Oxidative stress
is a major factor in a variety of neurodegenerative diseases [45].
NPC cells displayed a number of changes in gene expression that
are associated with the generation of reactive oxygen and nitrogen
species (Table 4). CHGA (chromogranin A), a component of
Alzheimer’s disease plaques [46], induces nitric oxide efflux from
microglia, a key step in neurodegeneration [47]. Components of
the phagocytic NADPH oxidase (CYBB, NCF4) that can generate
reactive oxygen species were upregulated [48]. Correspondingly,
a number of genes that respond to oxidative stress (MT1G, MT3,
GPX3 and GSTM2) were also upregulated in NPC fibroblasts.
Components of the mitochondrial electron transport chain were
also upregulated. This may indicate a compensatory response to
a disruption in electron transport chain function as seen in other
neurodegenerative diseases such as Parkinson’s. Reduced electron
transport chain activity has been associated with reactive oxygen
species production [49].
Altered levels of the metal ions copper, zinc and iron have been
observed in Alzheimer’s disease. The disruption in steady state
levels of iron and copper may play a role in oxidative damage
[50,51]. NPC fibroblasts demonstrated enhanced expression of
a wide range of transporters and solute carriers, suggesting that the
cells are electro-physiologically challenged (Table S1). Genes
involved in iron homeostasis and copper and zinc transport were
also upregulated, suggestive of an alteration in the cellular
homeostasis of these cations (Table S2).
Pleiotropic Changes in Membrane Trafficking
Factors
The increased cholesterol in NPC late endosomes and lysosomes
interferes with transport of proteins between these compartments
(cf. [52]). Consequently, proteins involved in membrane traffick-
ing and in particular, lysosome biogenesis, may be upregulated to
compensate for this defect. The lysosomal hydrolase, cathepsin B,
was upregulated in NPC cells. Both cathepsin B and cathepsin D
can function as beta-secretase enzymes, and are partially
mislocalized to early endosomes in Alzheimer’s disease [53,54].
We have shown elsewhere that in NPC cells, the cation-
independent mannose 6-phosphate receptor (CI-MPR) is upre-
gulated 1.6 fold at the protein level, along with two proteins
involved in its recycling to the Golgi complex: Rab9 GTPase and
the Rab9 effector, p40 [52]. p40 mRNA showed a 1.3 fold
upregulation in our dataset (Table S3); CI-MPR and Rab9 were
not present among the final array data elements. The cation-
dependent (CD)-MPR was upregulated 1.5 fold in our microarray
analyses (Table S3). This may be in part to compensate for this
protein’s rapid degradation in NPC fibroblasts [52].
In addition to the MPR trafficking components, many key
factors required for membrane traffic were upregulated (Table S3).
This includes as many as 8 Rab GTPases and numerous Rab
interacting proteins and GTPase activating proteins (TBC-domain
containing proteins), and several coat complexes involved in
transport vesicle assembly. Rab proteins are general regulators of
membrane traffic and have been of particular interest in NPC-
disease, as overexpression of several Rabs appears to reverse the
cholesterol accumulation phenotype in cell culture [reviewed in
52]. The BLOC1S1 protein complex that is key in the biogenesis
of lysosome related organelles was upregulated 2.4 fold (Table S3),
and an AP3-subunit key for synaptic vesicle recycling was also
upregulated 1.3 fold. Loss of AP3 leads to hippocampal granule
deficiency in mice deficient in this component [55]. A number of
so-called SNARE proteins and general membrane traffic compo-
nents including SEC22 and SEC24 were also upregulated. These
latter two proteins participate in protein transport from the
endoplasmic reticulum to the Golgi complex.
Multiple kinesin, myosin and dynein motors were upregulated,
perhaps to compensate for the inhibition of vesicle motility
characteristic of cells lacking NPC1 function [56,57]. Additional
cytoskeletal regulatory proteins including annexin A13 and A6,
ankyrin2, several Rho GTPase activating proteins and actin
related protein 3 were all upregulated. Many of these changes
likely reflect compensatory responses to cholesterol and sphingo-
lipid accumulation-triggered defects.
Table 4. Genes involved in oxidative stress that are upregulated in NPC fibroblasts.
..................................................................................................................................................
Accession number Symbol Name Fold Change False Discovery Rate
AI039375 ALDH7A1 Aldehyde dehydrogenase 7 family, member A1 1.5 0.7
AI301973 CHGA Chromogranin A (parathyroid secretory protein 1) 2.1 0
AA463492 CYBB Cytochrome b-245, beta polypeptide (chronic granulomatous disease) 1.4 2.4
AA508838 DDAH1 Dimethylarginine dimethylaminohydrolase 1 2 0.1
AI271623 DUOX1 Dual oxidase 1 1.4 4.5
AA664180 GPX3 Glutathione peroxidase 3 (plasma) 2.5 0
AA290737 GSTM2 Glutathione S-transferase M2 (muscle) 1.5 1.9
AI648396 HMOX1 Heme oxygenase (decycling) 1 1.6 3.6
N66278 JUND Jun D proto-oncogene 1.8 0.4
AI745626 MT1G Metallothionein 1G 1.7 0.2
AI362950 MT3 Metallothionein 3 (growth inhibitory factor (neurotrophic)) 1.4 0.7
AA969460 NCF4 Neutrophil cytosolic factor 4, 40kDa 1.9 0.2
H01039 NOS3 Nitric oxide synthase 3 (endothelial cell) 1.8 0.1
AA405415 TXNRD1 Thioredoxin reductase 1 1.6 0.4
AI185559 TXNRD3 Thioredoxin reductase 3 1.4 0.8
DOI: 10.1371/journal.pone.0000019.t004
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Gene expression analysis of fibroblasts from patients with
Niemann-Pick type C have revealed many intriguing similarities
with classic neurodegenerative diseases. Further study of newly
identified candidate genes are likely to reveal important clues to
the pathophysiology of this genetic disorder.
MATERIALS AND METHODS
Cells
NPC1
I1061T homozygous fibroblasts GM18453, GM17909 and
the heterozygous GM03123 fibroblast cell line containing the
I1061T mutation were obtained from Coriell cell repositories
(Camden, NJ.) and NPC1
I1061T homozygous fibroblasts 83.16 and
59413 were obtained from Dr. John O’Brien (Mayo Clinic,
Rochester, MN). Normal skin fibroblasts AG10803, GM09503,
GM05659 and GM03726 were obtained from the Coriell Cell
Repository. All fibroblasts were cultured in DMEM containing
10% fetal bovine serum. Cells were harvested at 50–70%
confluency.
Microarray procedures and Data analysis
mRNA was isolated with the FastTrack 2.0 mRNA isolation kit
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). A reference RNA comprised of 10 cell lines was used as the
control for each hybridized sample (Stratagene, La Jolla, CA).
Both sample and reference RNAs were amplified using the
MessageAmp II aRNA amplification kit (Ambion, Austin, TX).
Human cDNA microarrays consisting of ,43,000 elements were
obtained from the Stanford University functional genomics facility
[58]. Hybridizations were conducted essentially as described [59].
The selected genes had .2 fold intensity ratio/background and
were measurable in at least 80% of the data set. The resulting
output was grouped by hierarchical clustering [60]. The two sets of
genes were analyzed by significance analysis of microarrays (SAM)
using 100 iterations in the two-class, unpaired data option [12].
Immunoblots
Normal (AG10803) or NPC (GM03123) skin fibroblasts were
washed 3 times with PBS, followed by incubation with RIPA
buffer for 15 min. Lysates were centrifuged at 100,000 x g for
10 min and equal amounts of protein were analysed by
immunoblot using commercially available antibodies. Signals were
detected by chemiluminescence (Perkin Elmer Life Sciences Inc.,
Boston, MA). Antibodies and their sources were: Rabbit anti-
FE65L1 (APPB2), Dr. Suzanne Guenette, Harvard Medical
School; rabbit anti-BACE, Santa Cruz Biotechnology, Inc; Mouse
anti-Nicastrin, BD transduction Laboratories; Rabbit anti-PSEN1
and APP-CT, Dr. William Mobley, Stanford School of Medicine.
Data deposition
Original microarray data have been deposited in the Stanford
Microarray Database: http://smd.stanford.edu
SUPPORTING INFORMATION
Table S1 Gene encoding channels, transporters and solute
carriers that are upregulated in NPC fibroblasts.
Found at: doi:10.1371/journal.pone.0000019.s001 (0.07 MB
DOC)
Table S2 Genes involved in metal transport and homeostasis
that are upregulated in NPC fibroblasts.
Found at: doi:10.1371/journal.pone.0000019.s002 (0.03 MB
DOC)
Table S3 Genes involved in membrane traffic and the
cytoskeleton that are upregulated in NPC fibroblasts.
Found at: doi:10.1371/journal.pone.0000019.s003 (0.09 MB
DOC)
Dataset S1 This excel file presents SAM results for this data set,
sorted alphabetically. False discovery rates are all ,2%.
Found at: doi:10.1371/journal.pone.0000019.s004 (2.47 MB
XLS)
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